Manel Esteller

Institut d'Investigació Biomèdica de Bellvitge

Life & Medical Sciences

Manel Esteller (Sant Boi de Llobregat, Barcelona, Catalonia, Spain, 1968) graduated in Medicine with Honours from the Universitat de Barcelona in 1992, where he also obtained his PhD degree in molecular genetics in 1996. He was an Invited Researcher at the School of Biological and Medical Sciences at the University of St. Andrews (Scotland, UK) . From 1997 to 2001, Dr. Esteller was a researcher at the Johns Hopkins University and School of Medicine (Baltimore, USA) where he was decisive in establishing promoter hypermethylation of tumour suppressor genes as a common hallmark of all human tumours. From October 2001 to September 2008 Manel Esteller was the leader of the CNIO Cancer Epigenetics Laboratory. Currently, Dr Manel Esteller is Director of the Cancer Epigenetics and Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL) and Chairman of Genetics at the School of Medicine in the University of Barcelona..

Research interests

-Definition of the Epigenome of Cancer Cells: Profile of DNA methylation and histone modifications in tumor suppressor genes and repetitive sequences in cancer. Global and gene-specific definition of aberrant epigenetic changes and functional consequences in transcription regulation, DNA repair and chromosome instability. -Study of the Epigenetics Machinery and Mechanisms: Role and function of DNA methyltransferases (enzymes that maintain DNA methylation), specificity of methyl-CpG binding domain proteins (the nuclear factors that recognize DNA methylation), analysis of biological properties of histone deacetylases and methyltransferases (enzymes that modify histones). -Study of Mutations in the Epigenetic Machinery: The mechanisms underlying the disruption of the epigenetic landscape in transformed cells are unknown. -Study of the Epigenetic and Genetic Disruption of Non-Coding RNAs in Human Cancer. -Characterization of the Epitranscriptome in Human Diseases.

Selected publications

- Anadon C, van Tetering G, Ferreira HJ, Moutinho C, Martínez-Cardús A, Villanueva A, Soler M, Heyn H, Moran S, Castro de Moura M, Setien F, Vidal A, Genesca E, Ribera JM, Nomdedeu JF, Guil S & Esteller M 2017, 'Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia', Leukemia, 31, 1622-5. 

- Vidal E, Sayols S, Moran S, Guillaumet-Adkins A, Schroeder MP, Royo R, Orozco M, Gut M, Gut I, Lopez-Bigas N, Heyn H & Esteller M 2017, 'A DNA Methylation Map of Human Cancer at Single Base-Pair Resolution', Oncogene, 36, 40, 5648 - 5657.

- Wouters J, Vizoso M, Martinez-Cardus A, Carmona FJ, Govaere O, Laguna T, Joseph J, Dynoodt P, Aura C, Foth M, Cloots R, van den Hurk K, Balint B, Murphy IG, McDermott EW, Sheahan K, Jirström K, Nodin B, Udupi GM, van den Oord JJ, Gallagher WM & Esteller M 2017, 'Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma', Bmc Medicine, 15, 101.

- Pérez-Salvia M, Simó-Riudalbas L, Llinàs-Arias P, Roa L, Setien F, Soler M, Castro de Moura M, Bradner JE, Gonzalez-Suarez E, Moutinho C & Esteller M 2017, 'Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer', Oncotarget, 8, 31, 51621 - 51629.

- Moran S, Martinez-Cardus A, Boussios S & Esteller M 2017, 'Precision Medicine Based in Epigenomics: The Paradigm of Carcinoma of Unknown Primary', Nature Reviews Clinical Oncology, 14, 11, 682 - 694.

- Esteller M & Pandolfi PP 2017, 'The Epitranscriptome of Non-coding RNAs in Cancer', Cancer Discovery, 7, 359-68, 2017.

Selected research activities

- Chairman of Genetics, School of Medicine, University of Barcelona.

- Best Ideas in Health Award, Diario Medico.

- Patron Biomedical Sciences Graduation Ceremony, University of Lleida.

- “Carlemagne Falcon” Award, Girona.